Influence of atorvastatin on hospital acquired pneumonia in patients with acute ischemic stroke

Yuetian YU,Cheng ZHU,Enqiang MAO,Liang SHU,Rong YIN,Yujie LI,Chunyan LIU,Jianguo CAO,Yuan GAO
DOI: https://doi.org/10.16150/j.1671-2870.2015.02.017
2015-01-01
Abstract:Objective:To study the influence of long-term atorvastatin treatment prior to ischemic stroke on the inci-dence of hospitalacquired pneumonia (HAP) and levels of inflammatory markers. Methods:A total of 492 patients with a-cute ischemic stroke and Glasgow Coma Scale≤8 from 4 teaching hospitals were enrolled. Patients with prior atorvastatin treatment were assigned to atorvastatin treatment group (n=268, PG), and the others were assigned to no treatment group (n=224, NG). All the patients were given 20 mg atorvastatin every night during their stay in intensive care unit. Incidence of HAP and 28-day mortality were calculated. Levels of inflammatory markers [white blood cell (WBC), procalcitonin (PCT), tumor necrosis factor-alpha( TNF-α), interleukin-6(IL-6)] in blood serum were detected. Adverse events related to a-torvastatin treatment were documented. Results: There were no significant differences in incidence of HAP and 28-day mortality rate between PG and NG groups (25.74% vs. 24.55%, P>0.05; 50.72% vs. 58.18%, P>0.05, respectively). The incidence of ventilator associated pneumonia (VAP) was not significantly different between the two groups (41.94% vs 46.24%, P>0.05). However, prior atorvastatin treatment did influence the mortality of VAP (36.54% vs 58.14%, P=0.041) and was proved to be a protective factor (HR=0.564;95% CI, 0.310-0.825, P=0.038). Levels of TNF-αand IL-6 in VAP patients were lower in PG group than in NG group (P<0.01). Conclusions:Prior atorvastatin treatment can reduce morta-lity of VAP in patients with ischemic stroke, and down-regulates serum levels of TNF-αand IL-6.
What problem does this paper attempt to address?